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Cancer	 treatment,	 especially	 that	 for	 breast	 and	 lung	 cancer,	 has	 entered	 a	 new	


















mechanisms	 of	 afatinib	 resistance	 in	HER2-driven	 gastric	 cancer.	Our	 results	 also	
indicated	that	treatment	strategies	targeting	individual	mechanisms	of	resistance	are	
key	to	overcoming	such	resistance.
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1  | INTRODUC TION
Thanks	 to	 the	 dramatic	 development	 of	 genome	 analysis	 technol-










molecular	 drug	 for	 which	 phase	 III	 clinical	 trials	 have	 been	 per-
formed.	Neither	the	TyTAN	trial	nor	the	LOGiC	trial	demonstrated	




we	 reported	 the	 antitumor	 effect	 of	 afatinib	 in	 HER2-amplified	
gastric	cancer.5	Although	both	trastuzumab	and	afatinib	are	HER2-
targeted	drugs,	 trastuzumab	 is	a	humanized	 IgG1	monoclonal	an-
tibody6	and	afatinib	 is	a	receptor	tyrosine	kinase	(RTK).7	Because	
the	 mechanisms	 of	 these	 2	 drugs	 are	 totally	 different,	 afatinib	
could	be	another	treatment	option	for	gastric	cancer.	However,	 it	





we	 established	 2	 afatinib-resistant	 gastric	 cancer	 cell	 lines	 and	
analyzed	 the	mechanisms	 of	 acquired	 resistance.	 In	 addition,	we	
investigated	 treatment	 strategies	 for	 these	 afatinib-resistant	 cell	
lines	so	as	to	contribute	to	the	development	of	precision	medicine	
for	gastric	cancer	patients.
2  | MATERIAL S AND METHODS





crizotinib	 and	 cabozantinib	 were	 purchased	 from	 Synkinase	 (San	
Diego,	CA,	USA),	Sigma-Aldrich	(St.	Louis,	MO,	USA),	and	ChemScene	
(Monmouth	 Junction,	 NJ,	 USA),	 respectively.	 Dasatinib	 was	 pur-
chased	from	Bristol-Myers	Squibb	(New	York,	NY,	USA).
2.2 | DNA and RNA extraction




Reverse	Transcription	Kit	 (Thermo	Fisher	Scientific,	 San	 Jose,	CA,	
USA).	These	processes	were	performed	according	to	the	manufac-
turer's	instructions.
2.3 | Copy number and gene expression assay





Scientific),	 respectively.	 Both	 the	 copy	 number	 variation	 and	










the	 transmembrane	 domain	 and	 the	 kinase	 domain	 of	HER2,	 and	
exons	9	and	20	of	PIK3CA	were	analyzed	 in	the	direct	sequencing	
















tor	 (phospho-IGF-1R)	 (Tyr1135/1136),	 MET,	 p-MET(Tyr1234/1235),	
YES,	 Src,	 p-Src	 (Tyr416),	 ALDH1A1,	 ABCB1,	 E-cadherin,	 vimentin	
and	 p-AXL(Tyr702)	 (Cell	 Signaling	 Technology,	 Danvers,	 MA,	 USA),	
AXL	 (R&D	 Systems,	 Minneapolis,	 MN,	 USA),	 and	 actin	 (Santa	 Cruz	
Biotechnology,	Dallas,	TX,	USA).	The	secondary	antibodies	used	in	this	
study	were	as	 follows:	 goat	 anti–mouse	 IgG-HRP,	 goat	 anti-rat	 IgG-
HRP	and	donkey	anti–goat	IgG-HRP	(Santa	Cruz	Biotechnology).
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in	 accordance	with	 the	Policy	on	 the	Care	 and	Use	of	 Laboratory	




RPMI	 1640	 and	 50	 μL	 of	 Corning	Matrigel	 Basement	Membrane	




into	 3	 groups:	 an	 afatinib	 group	 (20	 mg/kg/day),	 a	 combination	
therapy	group	 (afatinib,	 20	mg/kg/day	 and	 cabozantinib,	100	mg/
kg/day)	 and	 a	 control	 group	 (placebo).	 The	 drugs	 were	 diluted	 in	
0.5	w/v	 (%)	methyl	 cellulose	 (Wako	Pure	Chemical	 Industries)	 and	
were	orally	administered	5	 times	a	week	 for	3	weeks.	We	started	




and	was	 calculated	 using	 the	 following	 empirical	 formula:	Volume	
(mm3)	=	length	(longest	diameter)	×	width	(shortest	diameter)2	×	0.5.
3  | RESULTS
3.1 | Establishment of afatinib‐resistant gastric 
cancer cell lines
Two	 gastric	 cancer	 cell	 lines,	 N87	 and	 SNU216,	were	 exposed	 to	 a	
high	concentration	of	afatinib	(2	μmol/L)	intermittently	for	more	than	




MTS	assay	 to	confirm	 the	successful	establishment	of	 resistant	cells	
(Table 1).





the	 amplification	of	HER2	 (Figure	1A),	 but	 the	gene	expression	of	
HER2	 was	 significantly	 downregulated	 compared	 with	 that	 in	 the	
parent	 cells	 (Figure	 1B).	 Likewise,	 western	 blotting	 demonstrated	
the	 downregulation	 of	 total	 HER2	 in	 both	 afatinib-resistant	 cell	








Cell line Characteristics HER2 amplification IC50 (nmol/L)
N87 Parental	cell	line Yes 3.1
N87-AR Afatinib	resistant	cell	line Yes 1089.6
SNU216 Parental	cell	line Yes 29.0
SNU216-AR Afatinib	resistant	cell	line Yes 4431.7
TA B L E  1   IC50	value	for	afatinib	and	
HER2	alteration	in	parental	and	afatinib-
resistant	cell	lines
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ergistic	 effect	 based	 on	 their	CI	 (Figure	 S1A,B).	When	 the	 2	MET	
inhibitors	 were	 compared,	 cabozantinib	 was	 more	 effective	 than	






























3.5 | Acquisition of Yes1 amplification in afatinib‐
resistant cell lines
Next,	 we	 performed	 a	 copy	 number	 assay	 of	 YES1,	 a	 member	 of	
the	 Src	 family,	 in	N87-AR	 and	 SNU216-AR.	Yes1	was	 amplified	 in	






Unlike	 crizotinib	 or	 cabozantinib	 in	 the	 MET-amplified	 resistant	





HER2,	 and	dasatinib	downregulated	p-Src,	 as	 expected.	Afatinib	
suppressed	 the	 activation	 of	 AKT	 in	 afatinib-resistant	 cells,	 and	
dasatinib	 also	 downregulated	 p-HER2	 unexpectedly.	 Although	




line	 and	 found	 that	 dasatinib	monotherapy	was	 effective	 in	 this	
cell	line	as	well	(Figure	3E).
3.6 | Antitumor effect of cabozantinib in a 
xenograft mouse model
Based	on	the	results	of	an	 in	vitro	assay,	we	performed	an	 in	vivo	
assay	 to	examine	 the	effect	of	 combination	 therapy	using	afatinib	
and	cabozantinib	in	N87-AR.	The	combination	therapy	had	a	signifi-
cant	antitumor	effect	against	N87-AR	(Figure	4A,B).	Afatinib	also	had	
F I G U R E  2   MET	amplification	and	AXL	
overexpression	in	the	afatinib-resistant	
cell	lines	N87-AR.	A,	Copy	number	assay	
































apy	with	 afatinib	 and	 cabozantinib	 and	 (ii)	 dasatinib	monotherapy	
were	 capable	 of	 overcoming	 the	 abovementioned	mechanisms	 of	
resistance,	respectively.
The	 gene	 amplification	 of	MET	 has	 already	 been	 reported	 as	 a	
mechanism	of	afatinib	resistance	 in	 lung	cancer.18	AXL	upregulation	











Previously,	 we	 reported	 that	 YES1	 amplification	 mediates	
resistance	 to	 lapatinib,	 a	 dual	 inhibitor	 of	 EGFR	 and	 HER2,	 in	
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HER2-amplified	breast	cancer.24	Based	on	the	results	of	this	study,	
we	 are	 convinced	 that	YES1	plays	 an	 important	 role	 in	 the	 acqui-











differences	 between	 the	 parental	 cells	 and	 the	 afatinib-resistant	
cells	 were	 found	 in	 these	 analyses.	 Taking	 into	 consideration	 the	





supposed	that	 the	microenvironment,	 including	the	existence	of	 fi-
broblasts	or	stromal	cells,	promoted	the	efficacy	of	afatinib	treatment,	
although	 the	 detailed	 mechanism	 remains	 unclear.	 Nevertheless,	
the	 effect	 of	 afatinib	 against	N87-AR	was	 quite	 limited,	 compared	
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In	this	study,	dasatinib	suppressed	the	activation	of	HER2	in	ad-
dition	 to	 Src.	 Some	 articles	 have	 already	 reported	 the	 interaction	
of	 Src	 family	proteins	 and	HER2.36,37	This	 phenomenon	might	 ex-
plain	the	reason	why	dasatinib	monotherapy	had	a	remarkable	an-










tially	be	another	 therapeutic	option	 in	 the	 treatment	of	HER2-am-
plified	gastric	cancer	cells,	and	not	just	for	afatinib-resistant	cells.
In	 conclusion,	 we	 identified:	 (i)	MET	 amplification	 with	 AXL	
overexpression	and	 (ii)	Yes1	amplification	as	mechanisms	of	afa-
tinib	resistance	in	gastric	cancer	cells.	Combination	therapy	with	
afatinib	 and	 cabozantinib	 or	 dasatinib	monotherapy	were	 capa-
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